The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Fri, 20th Mar 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

InterContinental Hotels Group, up 11%. The Holiday Inn and Crowne Plaza owner said demand is currently at the lowest level it has ever seen. To combat this, IHG is hoping to save about USD150 million through salary cuts, including "substantial" reduction in salary and incentives from its board and executive committee. Also, IHG will pull its final dividend of 85.9 US cents - saving about USD150 million - and said it will delay any further dividends until "visibility has improved". The hotel owner will also delay renovations and relax brand standards. Turning to trading, IHG said its global revenue per available room was down 6% in January and February, with a flat performance in the US being offset by a catastrophic drop in Greater China. In February, RevPAR in Greater China was down 90% year on year.

----------

Carnival, up 5.2%. The cruise operator said revenue for the first quarter increased 2.1% to USD4.8 billion from USD4.7 billion a year ago. However, Carnival swung to a first-quarter loss, with earnings dented by disruption due to the early days of the current Covid-19 pandemic. The company recorded a GAAP net loss of USD781 million, or USD1.14 per share, for the quarter ended February 29. This compares to net income of USD336 million, or earnings per share of USD0.48, for the first quarter a year ago. The impact of Covid-19 on the first quarter's net loss was around USD0.23 per share, the firm said, taking into account cancelled voyages and disruptions. Carnival said Covid-19 will have a "material negative impact" on its financial results and liquidity.

----------

FTSE 250 - WINNERS

----------

Future, up 30%. The media company said declines in its travel magazine portfolio have been offset by its grocery titles, resulting in "strong" digital audience numbers. "The period started well with exceptionally strong digital audience numbers with the resultant beneficial flow through to eCommerce and digital advertising," Future said. As a result, the company expects its results for the six months to the end of March to be in line with internal expectations. "The recent weeks have been unprecedented. However, our business has continued to trade robustly, with the diversified strategy working well. As of today, we have seen limited impact on our digital revenues," Future said. Despite the "robust" trading, Future said it is implementing some profit protection measures.

----------

JD Wetherspoon, up 27%. The pub chain operator reported a rise in profit and revenue in the first half of its financial year, but has cancelled its dividend due to the uncertainty surrounding the Covid-19 outbreak. In the 26 weeks to January 26, Wetherspoon's recorded pretax profit of GBP57.9 million, up 15% from the GBP50.3 million seen in the same period the year before. Revenue was 4.9% higher year-on-year at GBP933.0 million from GBP889.6 million. Like-for-like sales in the first half of the financial year were 5.0% higher. Like-for-like bar sales increased by 4.2%, food sales by 5.6% and fruit/slot machines by 20%. Like-for-like hotel room sales decreased by 1.3%, however. Bar sales were 60% of total sales, Wetherspoons noted. Despite the strong performance, the bar owner has cancelled its interim dividend - owing to the uncertainty caused by the spread of Covid-19.

----------

FTSE 250 - LOSERS

----------

Inchcape, down 3.1%. The automotive retailer said it will suspend its share buyback programme due to uncertainty arising from the Covid-19 outbreak. Inchcape has completed around GBP25 million of the GBP150 million repurchase programme but will serve notice to its brokers to terminate the buyback effective from next Tuesday. "Inchcape has a strong balance sheet and remains committed to its disciplined capital allocation policy, but the board believes this is the right decision at this time," the company said. As at the end of 2019, the company had cash of GBP423.0 million with total assets valued at GBP4.46 billion.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Faron Pharma, up 16%. The Finnish drug discovery company said its assets increased to EUR1.6 million in 2019 compared to just EUR400,000 reported a year earlier. As at December 31, the company said it had cash balances of EUR7.1 million compared to EUR4.1 million the year before. As a result, pretax loss narrowed to EUR13.3 million from EUR20.1 million year-on-year. The company did not generate any revenue during the year as it is currently focused on the development of Clevegen, a novel cancer immunotherapy.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Christie Group, down 5.5%. The financial services provider said it expects its 2019 results to be in line with expectations. The company said it has benefited from the profitable sale of an office building, as mentioned in our Interim results statement. However, Christie noted that its business - which operate in the hospitality, retail, medical and educational fields - took a hit from the Covid-19. This is primarily as a result of having limited access to certain of its clients' premises. "It is not currently possible to quantify the full effect of Covid-19 related disruption on our business for 2020 or beyond," said Christie in its statement Friday.

----------

Tracsis, down 1.7%. The traffic data provider said it is not possible to accurately quantify the impact on the second-half trading and therefore full year expectations amid rapidly changing situation with coronavirus. Tracsis said it expects the Rail Technology & Services division to have resilience as it derives most of its income from highly recurring product sales. However, parts of the Traffic & Data Services division are forecast to be hurt by Covid-19. In particular, the company's events businesses SEP and CTM both derive a significant amount of revenue from major UK based outdoor events, and in recent days Tracsis said it has been notified by some major clients that events scheduled for this summer will either be cancelled or postponed to the autumn. Tracsis said it expects further events to be cancelled or postponed in due course.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
13 Oct 2022 21:17

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more
5 Apr 2022 20:45

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Mar 2022 13:21

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.